Routine use of commercial antibiotic-loaded bone cement in primary total joint arthroplasty: a critical analysis of the current evidence
- PMID: 30963068
- PMCID: PMC6409235
- DOI: 10.21037/atm.2018.11.50
Routine use of commercial antibiotic-loaded bone cement in primary total joint arthroplasty: a critical analysis of the current evidence
Abstract
Antibiotic-loaded cement (ABLC) has been widely utilized as an adjuvant treatment for patients with periprosthetic joint infection (PJI) but has also evolved to play a prophylactic role against infection in primary total joint arthroplasties (TJA). Nevertheless, there is currently a paucity of studies that systematically investigated this concept. This review aimed at answering the following questions: (I) Can routine use of ABLC help reduce the current infection rates in primary TJA? (II) What are the risks associated with this approach? And (III) can routine use be justified in primary TJA from an economic standpoint? Multiple databases were queried including PubMed, EMBASE, EBSCO Host, and SCOPUS. Studies published between January 1, 1990 and March 31, 2018 were reviewed. Inclusion criteria were studies reporting: (I) clinical outcomes of routine use of ABLC in primary hip and knee arthroplasty with 2-year minimum follow-up, (II) complications related to the use of ABLC, (III) cost of using ABLC. The final analysis included 24 studies. Data from multiple studies demonstrate contradictory results for infection rates when ABLC is used in all primary procedures with a majority of studies showing similar infection rates between ABLC and plain cement. The main concerns associated with routine use of ABLC are negative effects on the mechanical stability of cement, possible systemic and local toxicity of the absorbed antibiotic, and development of resistant bacterial strains. However, current literature has not clinically validated these concerns. Lastly, with an estimated increase in 117 million dollars with the routine use of ABLC in only 50% of TJAs performed each year, it is difficult to justify the use of ABLC without clear superiority in reducing infection. The use of ABLC has undeniably changed the way orthopaedic surgeons deal with PJI today. However, the large-scale, prophylactic use of ABLC in primary TJAs requires further research and justification.
Keywords: Antibiotic-loaded bone cement; adjuvant; infection; total joint arthroplasty.
Conflict of interest statement
Conflicts of Interest: MA Mont: board or committee member of AAOS; paid consultant of Abbott, Cymedica, Mallinckrodt Pharmaceuticals, Pacira, Performance Dynamics Inc., Sage; paid consultant and research support of DJ Orthopaedics, Johnson & Johnson, Ongoing Care Solutions, Orthosensor, TissueGene; editorial or governing board of Journal of Arthroplasty, Journal of Knee Surgery; IP royalties of Microport; research support of National Institutes of Health (NIAMS & NICHD); editorial or governing board of Orthopedics, Surgical Techniques International; stock or stock options of Peerwell; IP royalties, paid consultant and research support of Stryker. The other authors have no conflicts of interest to declare.
Figures
Similar articles
-
Antibiotic containing bone cement in prevention of hip and knee prosthetic joint infections: A systematic review and meta-analysis.J Orthop Translat. 2020 May 8;23:53-60. doi: 10.1016/j.jot.2020.04.005. eCollection 2020 Jul. J Orthop Translat. 2020. PMID: 32489860 Free PMC article. Review.
-
The cost-effectiveness of antibiotic-loaded bone cement versus plain bone cement following total and partial knee and hip arthroplasty.J Orthop. 2020 Jan 25;20:217-220. doi: 10.1016/j.jor.2020.01.029. eCollection 2020 Jul-Aug. J Orthop. 2020. PMID: 32051672 Free PMC article.
-
Prophylactic use of antibiotic-loaded bone cement in primary total knee arthroplasty: Justified or not?Indian J Orthop. 2009 Jul;43(3):259-63. doi: 10.4103/0019-5413.53456. Indian J Orthop. 2009. PMID: 19838348 Free PMC article.
-
Prophylactic use of antibiotic bone cement: an emerging standard--in opposition.J Arthroplasty. 2004 Jun;19(4 Suppl 1):73-7. doi: 10.1016/j.arth.2004.04.006. J Arthroplasty. 2004. PMID: 15190554 Review.
-
The Economics of Antibiotic Cement in Total Knee Arthroplasty: Added Cost with No Reduction in Infection Rates.J Arthroplasty. 2019 Sep;34(9):2096-2101. doi: 10.1016/j.arth.2019.04.043. Epub 2019 Apr 26. J Arthroplasty. 2019. PMID: 31122848
Cited by
-
Antibiotics in Bone Cements Used for Prosthesis Fixation: An Efficient Way to Prevent Staphylococcus aureus and Staphylococcus epidermidis Prosthetic Joint Infection.Front Med (Lausanne). 2021 Jan 20;7:576231. doi: 10.3389/fmed.2020.576231. eCollection 2020. Front Med (Lausanne). 2021. PMID: 33553196 Free PMC article.
-
Does antibiotic bone cement reduce infection rates in primary total knee arthroplasty?Eur J Orthop Surg Traumatol. 2023 Dec;33(8):3379-3385. doi: 10.1007/s00590-023-03557-3. Epub 2023 May 3. Eur J Orthop Surg Traumatol. 2023. PMID: 37133753
-
Chemerin/ChemR23 signaling mediates the effects of ultra-high molecular weight polyethylene wear particles on the balance between osteoblast and osteoclast differentiation.Ann Transl Med. 2021 Jul;9(14):1149. doi: 10.21037/atm-21-2945. Ann Transl Med. 2021. PMID: 34430590 Free PMC article.
-
Influence of chitosan and chitosan oligosaccharide on dual antibiotic-loaded bone cement: In vitro evaluations.PLoS One. 2022 Nov 30;17(11):e0276604. doi: 10.1371/journal.pone.0276604. eCollection 2022. PLoS One. 2022. PMID: 36449553 Free PMC article.
-
Cathodic voltage-controlled electrical stimulation and betadine decontaminate nosocomial pathogens from implant surfaces.mSphere. 2024 Feb 28;9(2):e0058323. doi: 10.1128/msphere.00583-23. Epub 2024 Feb 1. mSphere. 2024. PMID: 38299852 Free PMC article.
References
-
- Kurtz S, Ong K, Lau E, et al. Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007;89:780-5. - PubMed
Publication types
LinkOut - more resources
Full Text Sources